Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.
Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. Lévy Y, et al. Among authors: sereti i. Clin Infect Dis. 2012 Jul;55(2):291-300. doi: 10.1093/cid/cis383. Epub 2012 May 1. Clin Infect Dis. 2012. PMID: 22550117 Free PMC article. Clinical Trial.
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. Tavel JA, et al. Among authors: sereti i. J Infect Dis. 2003 Aug 15;188(4):531-6. doi: 10.1086/377285. Epub 2003 Jul 31. J Infect Dis. 2003. PMID: 12898439 Clinical Trial.
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT Jr, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, Kovacs JA. Read SW, et al. Among authors: sereti i. J Infect Dis. 2008 Sep 15;198(6):843-50. doi: 10.1086/591250. J Infect Dis. 2008. PMID: 18684102 Free PMC article.
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team. Sereti I, et al. Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20. Blood. 2009. PMID: 19380868 Free PMC article. Clinical Trial.
Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.
Lévy Y, Thiébaut R, Gougeon ML, Molina JM, Weiss L, Girard PM, Venet A, Morlat P, Poirier B, Lascaux AS, Boucherie C, Sereni D, Rouzioux C, Viard JP, Lane C, Delfraissy JF, Sereti I, Chêne G; ILIADE Study Group. Lévy Y, et al. Among authors: sereti i. AIDS. 2012 Mar 27;26(6):711-20. doi: 10.1097/QAD.0b013e3283519214. AIDS. 2012. PMID: 22301410 Clinical Trial.
255 results